Interoperability: biolog-id Technology Soon to Be Available From Inlog Software
6.7.2021 18:03:00 EEST | Business Wire | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Inlog, a software company dedicated to the medical sector, have announced today a strategic interoperability partnership for their solutions.
With a market presence of more than 30 years, Inlog has developed software suites that ensure the quality and the traceability of products throughout the transfusion supply chain. These software suites are used today by nearly 250 French and international clients, including an important part of University Hospitals.
To allow blood centers and hospitals to take advantage of the RFID technology, Inlog and biolog-id are partnering to guarantee the interoperability of the Edge Track (Hemo Server) and Edge Blood (CTS Server) software with the Biolog Data System modules from the Biolog Transfusion Solution.
By combining RFID tags containing essential information of blood products, connected equipment, and a dedicated transactional and decision-making software, Biolog Transfusion Solution secures the entire blood transfusion supply chain, from the donor to the recipient. Beyond reinforcing the safety of transfused patients, the solution optimizes in real-time the local and remote inventory management of these vital therapeutic products and allows them to be attributed nominatively remotely and safely.
“We are very pleased that Inlog, who is today a reference in the field of blood supply chain management, and biolog-id collaborate to propose their users and prospects an option for strengthening traceability and securing the transfusion chain based on our RFID solution”, says Bruno Chappert, CEO at biolog-id. “This interoperability agreement will enable us to offer transfusion professionals a new feature capable of improving their efficiency, optimizing working conditions while adapting to all types of structures, and finally facilitating the rapid implementation of these software solutions”.
“We are convinced that this interoperability agreement between biolog-id and Inlog will provide healthcare and transfusion facilities with better blood product management, enhanced safety and improved traceability”, underlines David Kalfon, President at Inlog. “The numerous combined advantages of biolog-id and Inlog solutions will allow the transfusion chain professionals to rationalize their operations and optimize their costs”.
The Inlog software and Biolog Transfusion Solution will be available under different technical models to allow simple, fast and modular integration by healthcare infrastructures and to meet users’ needs.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Inlog:
Founded in 1992, Inlog is one of the leading French software companies in the field of medical informatics for laboratory analysis, traceability of blood products in healthcare facilities and the various activities of blood transfusion centers.
Inlog designs and develops a range of software for the healthcare sector whose advantages in terms of robustness, reliability and ease of configuration are distinguished by all its customers. Motivated by a new management board, Inlog is initiating an ambitious project to use new technologies into its applications to make their use even more ergonomic and intuitive.
The Inlog software suites, CE marked, are used by more than 250 Healthcare institutions in France and around the world (Germany, Switzerland, Belgium, Canada, Hong Kong, etc.), including some prestigious partners such as the Etablissement Français du Sang, the Hôpitaux Universitaires Genevois and the Flemish Red Cross.
Inlog is currently supported by the French investment fund Abénex, a major player in private equity in France.
Company URL: https://www.inlog.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005565/en/
Contact information
biolog-id
Astrid Billard, astrid.billard@biolog-id.com
Inlog
David Delay,
david.delay@inlog.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom